SCHEMBL6934604

SCHEMBL6934604

Cn1c(NC[C@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc(Cl)c(Cl)c2)c1=O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 14/20 0.81
MAPK9 P45984 3/20 0.81
MAPK13 O15264 2/20 0.81
MAPK14 Q16539 2/20 0.81
MAP4K4 O95819 2/20 0.81
CSNK1D P48730 2/20 0.81
CDC42BPA Q5VT25 2/20 0.81
MINK1 Q8N4C8 2/20 0.81
PRKCD Q05655 2/20 0.81
EGFR P00533 1/20 0.81
ERBB2 P04626 1/20 0.81
LYN P07948 1/20 0.81
PRKACA P17612 1/20 0.81
MAPK8 P45983 1/20 0.81
MAPK12 P53778 1/20 0.81
MAPK10 P53779 1/20 0.81
MAP3K10 Q02779 1/20 0.81
PRKCZ Q05513 1/20 0.81
CAMK2B Q13554 1/20 0.81
CAMK2G Q13555 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6934599 1.00 PRKCI (0.81) PRKCIMAPK9MAPK13MAPK14MAP4K4
SCHEMBL6934602 1.00 PRKCI (0.81) PRKCIMAPK9MAPK13MAPK14MAP4K4
SCHEMBL6936189 0.92 PRKCI (0.77) PRKCIMAPK9MAPK13MAPK14MAP4K4
SCHEMBL6936191 0.92 PRKCI (0.77) PRKCIMAPK9MAPK13MAPK14MAP4K4
SCHEMBL6936194 0.92 PRKCI (0.77) PRKCIMAPK9MAPK13MAPK14MAP4K4
SCHEMBL27506329 0.90 MAPK9 (0.82) PRKCIMAPK9MAPK13MAPK14MAP4K4
Amg-548 SCHEMBL29395852 0.89 PRKCI (1.00) PRKCIMAPK9MAPK13MAPK14MAP4K4
Amg-548 SCHEMBL433426 0.89 PRKCI (1.00) PRKCIMAPK9MAPK13MAPK14MAP4K4
Amg-548 SCHEMBL433425 0.89 PRKCI (1.00) PRKCIMAPK9MAPK13MAPK14MAP4K4
Amg-548 SCHEMBL2409009 0.89 PRKCI (1.00) PRKCIMAPK9MAPK13MAPK14MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 US claimed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 US claimed
US-6649604-B2 Analgesics; antidiabetic agents; antiinflamamtory agents AMGEN INC. 2003-11-18 US disclosed
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 US disclosed
US-6420385-B1 INFLAMMATORY, PAIN AND DIABETES DISEASES, AMGEN INC. 2002-07-16 US disclosed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 US disclosed
EP-0948496-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE Amgen inc. (US) 1999-10-13 EP disclosed
WO-1998024780-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE AMGEN INC. (US) 1998-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073704-A1 Substituted pyridone compounds and methods of use IL6, IL1B, IL1A PRKCI 3717/4885MAPK9 1247/4885MAPK13 1577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.